Kane Biotech and ProgenaCare Global Launch revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
Kane Biotech Inc. and ProgenaCare Global LLP have announced the launch of revyve™ Antimicrobial Wound Gel, formerly known as coactiv+™ Antimicrobial Wound Gel. The rebranding aims to signify a fresh start for chronic wounds, offering a triple threat approach to wound care. The product combines Kane's patented coactiv+™ technology and PHMB with a non-ionic pluronic surfactant with thermo-gelling properties. This combination creates an easy-to-use gel that promotes wound healing in a moist environment while providing effective antimicrobial activity. The launch of revyve™ Antimicrobial Wound Gel is being unveiled at the Symposium on Advanced Wound Care (SAWC) Fall forum, where Kane Biotech and ProgenaCare will present alongside other industry leaders in the biotech and wound care sectors.
According to Howard Walthall, CEO of ProgenaCare, the revyve™ brand has received positive feedback from clinicians who appreciate the advanced technology and affordable price point. The companies are working towards expanding the clinical usage of the product before scaling up production in Q1.
This launch demonstrates the commitment of Kane Biotech and ProgenaCare to provide innovative and effective wound care solutions. The revyve™ Antimicrobial Wound Gel offers a promising approach to managing ulcers, burns, wounds, and surgical incisions, with potential applications in various adult populations.
For more information about revyve™ Antimicrobial Wound Gel, visit the official website at www.revyvegel.com.
Impact of revyve™ Antimicrobial Wound Gel Launch on New Businesses
The launch of revyve™ Antimicrobial Wound Gel by Kane Biotech Inc. and ProgenaCare Global LLP signifies a significant shift in the wound care industry. This innovative product, combining Kane's patented coactiv+™ technology and PHMB with a non-ionic pluronic surfactant, presents an opportunity for new businesses in the healthcare sector.
Revolutionizing Wound Care
The rebranding of coactiv+™ to revyve™ is more than just a name change; it represents a new approach to wound care. The triple threat approach offers a comprehensive solution for chronic wounds, providing an environment conducive to healing while also ensuring effective antimicrobial activity.
Market Reception and Expansion
The positive feedback from clinicians, as noted by ProgenaCare's CEO, Howard Walthall, indicates a strong market reception. This acceptance, coupled with an affordable price point, could pave the way for new businesses to enter and thrive in the wound care market.
Future Implications
The launch of revyve™ Antimicrobial Wound Gel at the Symposium on Advanced Wound Care Fall forum places it among industry leaders, setting a high standard for future products. For new businesses, this launch serves as a benchmark for innovation and effectiveness in wound care solutions. It underscores the importance of continuous innovation and the potential of advanced technology in transforming healthcare solutions.
.svg)
